Powerful Targeted Therapies Clinical Trial for
Abdominal Cancers
About clinical
trials
About abdominal
cancers
About the
therapy
Participate in
our clinical trial
Resources

Do you or a loved one have cancer (such as ovarian, pancreatic, colon, gastric, endometrial,
or breast) that has metastasized in your abdomen for which no standard therapy is available?

Current therapies are quite limited for combating these diseases; this is why
AREVA Med is sponsoring a Phase I clinical trial of ²¹²Pb-TCMC-Trastuzumab.

 
Clipboard Are you a potential candidate for this study?
Answer a few yes-no questions to find out.
 
Insight from our experts
"The novel technology behind this clinical trial has delivered very encouraging preclinical results and we are looking forward to potentially helping patients with aggressive metastatic abdominal cancers."


Ruby F. Meredith, M.D., Ph.D.

Principal investigator at the University of Alabama at Birmingham

"It is through clinical trials that progress has been made in the treatment of cancer over the past decades. Patients who volunteer for clinical trials have access to new approaches to treatment. There is no guarantee that an experimental treatment will benefit a specific patient, but individuals who participate in clinical trials sometimes have access to treatments years before they become standard therapy and through their involvement they are advancing science and helping other patients."

Christine White, M.D.
AREVA Med scientific committee member, Medical oncologist & former Chief Medical Officer at Biogen Idec
"Targeted alpha-particle emitter therapy is a novel approach to treating patients with disseminated metastatic cancer. Its effectiveness depends on mechanisms that are fundamentally different from those required for chemotherapy, it is, therefore, far less susceptible to resistance and has tremendous potential to have a substantial positive impact in patients with aggressive metastatic abdominal cancers."

George Sgouros, Ph.D.
AREVA Med scientific committee member & Professor and Director at Johns Hopkins University

Dr. Meredith
Dr. White
Dr. Sgouros
 
Radiolabeled antibody About the Phase I investigational agent, ²¹²Pb-TCMC-Trastuzumab  

Monoclonal antibodies can transport and deliver radioactive elements capable
of releasing sufficient amounts of energy to destroy tumor cells.

 Find out more

Contact us Copyright 2011